Growth and Neurodevelopment in Extremely Low-Birth-Weight Neonates Exposed to Postnatal Steroid Therapy

Judy L LeFlore; William D Engle

doi:10.1055/s-0031-1276738

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2011; 28(8): 635-642
DOI: 10.1055/s-0031-1276738

Growth and Neurodevelopment in Extremely Low-Birth-Weight Neonates Exposed to Postnatal Steroid Therapy

Judy L. LeFlore¹ , William D. Engle²

¹Department of Pediatrics, School of Nursing, The University of Texas at Arlington, Arlington
²The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Abstract

ABSTRACT

We compared postnatal growth and neurodevelopment in extremely low-birth-weight (<1000 g) neonates who did or did not receive postnatal steroid (PNS) therapy for bronchopulmonary dysplasia (BPD). One hundred seventy-three neonates with Bayley Scales of Infant Development II (BSID II) testing performed at 18- to 22-month adjusted age were studied. Growth parameters and BSID II scales were compared among three groups: group I, no BPD; group II, BPD, no PNS; group III, BPD and PNS exposure. A subset of 77 neonates' growth parameters were retrieved at 12-month adjusted age. Psychomotor Development Index (PDI) and Mental Development Index (MDI) scales were lower in group III versus groups I and II. Growth velocity (GV) was lower in group III versus group I and II during the initial hospital stay. In the subset, GV from birth to 1-year adjusted age and weight, length, and head circumference determined at 1-year adjusted age were similar among the groups. Multivariate analysis revealed a significant effect of group membership and cystic periventricular leukomalacia on PDI. These results suggest that a deleterious effect of PNS therapy on neurodevelopment can occur by a mechanism that does not impair overall growth or growth of head circumference.

KEYWORDS

Neonate - preterm - dexamethasone - bronchopulmonary dysplasia - chronic lung disease - neurodevelopment

Volltext

Referenzen

REFERENCES

1 Halliday H L. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate. 1999; 76 (Suppl 1) 29-40
2 Doyle L W, Davis P G, Morley C J, McPhee A, Carlin J B. DART Study Investigators . Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006; 117 75-83
3 Finer N N, Craft A, Vaucher Y E, Clark R H, Sola A. Postnatal steroids: short-term gain, long-term pain?. J Pediatr. 2000; 137 9-13
4 Tarnow-Mordi W, Mitra A. Postnatal dexamethasone in preterm infants is potentially lifesaving, but follow up studies are urgently needed. BMJ. 1999; 319 1385-1386
5 Barrington K J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001; 1 1
6 Leib S L, Heimgartner C, Bifrare Y D, Loeffler J M, Täauber M G. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res. 2003; 54 353-357
7 LeFlore J L, Salhab W A, Broyles R S, Engle W D. Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates. Pediatrics. 2002; 110 (2 Pt 1) 275-279
8 Shinwell E S, Karplus M, Reich D et al.. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000; 83 F177-F181
9 Baud O. Postnatal steroid treatment and brain development. Arch Dis Child Fetal Neonatal Ed. 2004; 89 F96-F100
10 Doyle L W, Halliday H L, Ehrenkranz R A, Davis P G, Sinclair J C. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005; 115 655-661
11 Watterberg K L. American Academy of Pediatrics. Committee on Fetus and Newborn . Policy statement—postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 2010; 126 800-808
12 Skidmore M D, Rivers A, Hack M. Increased risk of cerebral palsy among very low-birthweight infants with chronic lung disease. Dev Med Child Neurol. 1990; 32 325-332
13 Vohr B R, Wright L L, Dusick A M et al.. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics. 2000; 105 1216-1226
14 Papile L A, Tyson J E, Stoll B J et al.. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998; 338 1112-1118
15 Thorp J A, Jones P G, Peabody J L, Knox E, Clark R H. Effect of antenatal and postnatal corticosteroid therapy on weight gain and head circumference growth in the nursery. Obstet Gynecol. 2002; 99 109-115
16 Ehrenkranz R A, Younes N, Lemons J A et al.. Longitudinal growth of hospitalized very low birth weight infants. Pediatrics. 1999; 104 (2 Pt 1) 280-289
17 Tyson J E, Kennedy K, Broyles S, Rosenfeld C R. The small for gestational age infant: accelerated or delayed pulmonary maturation? Increased or decreased survival?. Pediatrics. 1995; 95 534-538
18 Papile L A, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92 529-534
19 Patel A L, Engstrom J L, Meier P P, Kimura R E. Accuracy of methods for calculating postnatal growth velocity for extremely low birth weight infants. Pediatrics. 2005; 116 1466-1473
20 Halliday H L, Ehrenkranz R A, Doyle L W. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2010; (1) CD001146
21 Halliday H L, Ehrenkranz R A, Doyle L W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009; (1) CD001145
22 Onland W, Offringa M, De Jaegere A P, van Kaam A H. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009; 123 367-377
23 Murphy B P, Inder T E, Huppi P S et al.. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001; 107 217-221
24 O'Shea T M, Kothadia J M, Klinepeter K L et al.. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999; 104 (1 Pt 1) 15-21
25 Yeh T F, Lin Y J, Huang C C et al.. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998; 101 E7
26 Whitelaw A, Thoresen M. Antenatal steroids and the developing brain. Arch Dis Child Fetal Neonatal Ed. 2000; 83 F154-F157
27 Jobe A H, Newnham J, Willet K, Sly P, Ikegami M. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics. 1998; 102 1116-1125
28 Jobe A H, Wada N, Berry L M, Ikegami M, Ervin M G. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol. 1998; 178 880-885
29 Huang W L, Beazley L D, Quinlivan J A, Evans S F, Newnham J P, Dunlop S A. Effect of corticosteroids on brain growth in fetal sheep. Obstet Gynecol. 1999; 94 213-218
30 Wagerle L C, DeGiulio P A, Mishra O P, Delivoria-Papadopoulos M. Effect of dexamethasone on cerebral prostanoid formation and pial arteriolar reactivity to CO2 in newborn pigs. Am J Physiol. 1991; 260 (4 Pt 2) H1313-H1318
31 Van Marter L J, Kuban K CK, Allred E et al.. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation?. Arch Dis Child Fetal Neonatal Ed. 2011; 96 F20-F29
32 Armstrong D L, Bagnall C, Harding J E, Teele R L. Measurement of the subarachnoid space by ultrasound in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2002; 86 F124-F126
33 Radmacher P G, Rafail S T, Adamkin D H. Nutrition and growth in VVLBW infants with and without bronchopulmonary dysplasia. Neonatal Intensive Care. 2004; 16 22-26
34 deRegnier R A, Guilbert T W, Mills M M, Georgieff M K. Growth failure and altered body composition are established by one month of age in infants with bronchopulmonary dysplasia. J Nutr. 1996; 126 168-175
35 Weiler H A, Paes B, Shah J K, Atkinson S A. Longitudinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone. Early Hum Dev. 1997; 47 271-286
36 Armstrong D L, Penrice J, Bloomfield F H, Knight D B, Dezoete J A, Harding J E. Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002; 86 F102-F107
37 Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics. 1995; 96 (5 Pt 1) 897-906

William D EngleM.D.

Professor of Pediatrics, University of Texas Southwestern Medical Center

5323 Harry Hines Blvd., Dallas, Texas 75390-9063

eMail: William.Engle@utsouthwestern.edu